JPMorgan Chase & Co. Raises Stock Position in Kura Oncology, Inc. (NASDAQ:KURA)

JPMorgan Chase & Co. lifted its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 0.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 409,241 shares of the company’s stock after buying an additional 3,092 shares during the period. JPMorgan Chase & Co.’s holdings in Kura Oncology were worth $7,997,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. nVerses Capital LLC purchased a new position in shares of Kura Oncology during the third quarter worth about $25,000. Point72 DIFC Ltd acquired a new stake in shares of Kura Oncology in the 3rd quarter valued at about $146,000. Quarry LP purchased a new position in Kura Oncology during the 2nd quarter worth approximately $196,000. Erste Asset Management GmbH acquired a new position in Kura Oncology during the third quarter worth approximately $215,000. Finally, Bellevue Group AG lifted its stake in Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after buying an additional 3,600 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on KURA. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 target price on shares of Kura Oncology in a report on Tuesday, November 19th. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Bank of America reduced their price target on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday, November 22nd. Finally, Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $26.00 to $19.00 in a report on Monday, October 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $27.38.

Kura Oncology Price Performance

Shares of NASDAQ:KURA opened at $7.26 on Wednesday. The firm’s 50 day moving average is $11.14 and its two-hundred day moving average is $16.61. The firm has a market capitalization of $564.57 million, a P/E ratio of -3.08 and a beta of 0.81. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 52 week low of $6.98 and a 52 week high of $24.17.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.